Third Generation Drug Gets FDA Nod

by Dr. Sunil Shroff on  November 17, 2007 at 5:56 PM Drug News
RSS Email Print This Page Comment
Third Generation Drug Gets FDA Nod
Chennai-based pharmaceuticals major Orchid Chemicals & Pharmaceuticals Ltd has received approval from the Food and Drug Administration (FDA) of the US for its infectious diseases drug.
Advertisement

The company said in a release Friday that the FDA has approved its abbreviated new drug application for Cefpodoxime Proxetil tablets.

Advertisement
The product is available in two dosage strengths of 100 mg and 200 mg.

Cefpodoxime Proxetil is a third-generation cephalosporin antibiotic, which has broad-spectrum activity against organisms causing infectious diseases.

With limited generic competition in this product, Orchid hopes to garner a sizeable market share and revenues in the US market, the company said Friday.

Source: IANS
MED/P
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Drug Toxicity Signature Drug Toxicity 
Advertisement

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement

Advertisement
Advertisement

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive